Shares of 60 Degrees Pharmaceuticals dropped 6% before the market opened as people wait for tafenoquine trial results.

SXTP · 60 Degrees Pharmaceuticals Inc.

The AI's read

The drug could address an illness with no FDA-approved treatment, but the report gives no evidence that it works for this illness. Tafenoquine is approved to prevent malaria, not babesiosis. Until trial data are reported, the story does not change what is known about the drug's prospects.